Background <p>Current immunotherapy regimens most often fail due to an insufficient T cell response and/or immune-related adverse events (irAEs) which lead to treatment discontinuation. Additionally, many cancers likely require combination immunotherapies which may further increase irAE. This is exemplified in our preclinical models of dual targeting of regulatory T cells with a phosphoinositide 3-kinase (PI3K) inhibitor and antibodies to LAG-3.…
Optimizing anti-PI3K{delta} and anti-LAG-3 immunotherapy dosing regimens in a mouse model of triple-negative breast cancer improves outcome by removing treatment-related adverse events
Journal for ImmunoTherapy of Cancer | | Lauder, S. N., Pires, A., Somerville, M., Capitani, L., Smart, K., Geary, J., Mills, E. M., Vanhaesebroeck, B., Godkin, A., Gallimore, A.
Topics: breast-cancer, blood-cancer, immunotherapy
Read the full article at Journal for ImmunoTherapy of Cancer